Oricula Therapeutics

Oricula Therapeutics was founded in 2013, with the mission of developing drugs that will prevent hearing loss as a result of using ototoxic drugs such as aminoglycosides which are important antibiotics, but whose side effects include hearing loss. They are currently in the process of filing for Investigational New Drug (IND) with the FDA.

Clinical trials to be announced.